Astria Therapeutics
ATXS
Market cap $359M

6.37 USD

-0.30

4.50%

At close Jul 11, 4:00 PM EDT

After hours

6.37

+0.00

0.00%

1 day

-4.50%

5 days

10.78%

1 month

10.02%

3 months

57.67%

6 months

-14.61%

Year to date

-28.99%

1 year

-43.38%

5 years

-83.23%

10 years

-99.18%

About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Employees: 78

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

46% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 13

5% more funds holding

Funds holding: 110 [Q4 2024] → 115 (+5) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

0.4% less ownership

Funds ownership: 103.75% [Q4 2024] → 103.35% (-0.4%) [Q1 2025]

6% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 36

40% less capital invested

Capital invested by funds: $523M [Q4 2024] → $311M (-$212M) [Q1 2025]

86% less call options, than puts

Call options by funds: $5K | Put options by funds: $36K

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$16

151%

upside

Avg. target

$37

476%

upside

High target

$47

638%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis	151%upside $16	Buy Reiterated	13 Jun 2025
Cantor Fitzgerald Timur Ivannikov	638%upside $47	Overweight Reiterated	14 May 2025
Cantor Fitzgerald Steven Seedhouse	638%upside $47	Overweight Initiated	29 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ATXS published over the past 30 days

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit

BOSTON, Mass.--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the 2025 US Hereditary Angioedema Association (HAEA) National Summit, taking place July 10-13, 2025 in Baltimore, Maryland. Timothy Craig, D.O., Professor of Medicine, Pediatrics, and Biomedical Sciences at Penn State University in Hershey, Pennsylvania, will.

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 119,860 shares of Astria's common stock on July 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were grante.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in a panel discussion at the Oppenheimer Innovators in Immunology & Inflammation (I&I) Summit on June 25 in New York, NY. Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a panel titled, “Advances in Dermatology: AD and CSU” on Wednesday, June 25 at 10:.

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These results demonstrated robust overall reduction in the mon.

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, taking place June 13-16, 2025 in Glasgow, United Kingdom. Dr. William Yang, M.D., FRCPC, FAAAAI, Managing Director and Chair, Ottawa Allergy Research Corporation, will present combined i.

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 62,000 shares of Astria's common stock on June 2, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on Wednesday, June 4th at 1:25pm ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff319/atxs/1878784. An archiv.

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary on May 31, 2025. Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at the University of California, San Diego, will present safety and efficacy data from.

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the Eastern Allergy Conference (EAC) in Palm Beach, Florida on May 30, 2025. Raffi Tachdjian, M.D., Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at the University of California, L.

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. “As a late-stage clinical company, we are focused on delivering on navenibart, a therapy with a trusted mechanism and modality, best-in-class profile, and the potential to change the way that people live with H.

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™